OCULAR THERAPEUTIX, INC.
BEDFORD, MA

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company incorporated in Florida with a focus on developing innovative therapies for eye diseases and conditions using its proprietary hydrogel platform technology. The company aims to streamline the current eye drop or injection treatments by creating sustained-release dosage forms that enhance patient compliance through consistent drug dosing. Among its lead product candidates, DEXTENZA™ (dexamethasone insert) 0.4 mg has completed Phase 3 clinical development for managing ocular pain and inflammation post-ophthalmic surgery. Additionally, OTX-TP (travoprost insert) is in the same phase for reducing intraocular pressure in glaucoma and ocular hypertension patients. Earlier-stage developments include OTX-TIC and intravitreal injections like OTX-TKI for retinal diseases, along with collaborations such as an anti-VEGF trap with Regeneron. Ocular Therapeutix’s notable FDA-approved product, ReSure® Sealant, is utilized to seal corneal incisions post-cataract surgery. The company's efforts aim at improving treatment effectiveness and patient adherence by addressing the complexities of current ophthalmic regimens. Founded on December 7, 2016, with its headquarters located in Bedford, MA (though incorporated in Florida), Ocular Therapeutix is led by Antony Mattessich as President. Additional leadership includes Donald Notman serving both as Treasurer and Secretary. The company was reinstated on March 7, 2019, signaling continued operations and a commitment to advancing ophthalmic care technologies. For more information about their cutting-edge biopharmaceutical advancements or to learn more about the hydrogel-based treatment solutions, visit oculartherapeutix.com.